Viking Global Investors
Viking Global Investors is a long/short equity hedge fund. The fund employs a bottom-up fundamental stock-picking strategy for its investments in equities in the U.S. and Europe. It focuses on the financial, telecommunication, media, technology, and consumer sectors. Viking Global Investors is based in New York and was founded in October, 1999 by Andreas Halvorsen, David Ott, and Brian Olson.
Messers. Halvorsen, Ott, and Olson worked together at Tiger Management Corp. All three left Tiger in early 1999.
View Older Stories View More Recent Stories
-
Form SCHEDULE 13G Oruka Therapeutics, Inc. Filed by: VIKING GLOBAL INVESTORS LP
-
Ensoma Announces $53 Million Financing to Support Key Clinical Milestones for EN-374 and Continued Development of In Vivo Hematopoietic Stem Cell Engineering Pipeline
-
Oruka Therapeutics raises $180 million in private placement
-
Oruka Therapeutics Announces $180 Million Private Placement
-
Revive Environmental Wins 2025 WEFTEC Innovative Technology Award for PFAS Annihilator® SCWO
-
Form SCHEDULE 13G SAIA INC Filed by: VIKING GLOBAL INVESTORS LP
-
Form N-PX VIKING GLOBAL INVESTORS For: Jun 30
-
Form SCHEDULE 13D/A BridgeBio Pharma, Inc. Filed by: VIKING GLOBAL INVESTORS LP
-
Form SCHEDULE 13G/A APi Group Corp Filed by: VIKING GLOBAL INVESTORS LP
-
Form SCHEDULE 13G/A Trevi Therapeutics, Inc. Filed by: VIKING GLOBAL INVESTORS LP
-
Form SCHEDULE 13G/A Oric Pharmaceuticals, Filed by: VIKING GLOBAL INVESTORS LP
-
Form SCHEDULE 13G/A BIOMARIN PHARMACEUTICAL Filed by: VIKING GLOBAL INVESTORS LP
-
Form SCHEDULE 13G/A REGAL REXNORD CORP Filed by: VIKING GLOBAL INVESTORS LP
-
Form SCHEDULE 13G/A Roivant Sciences Ltd. Filed by: VIKING GLOBAL INVESTORS LP
-
Form 13F-HR VIKING GLOBAL INVESTORS For: Jun 30
-
KeyBanc Reiterates Sector Weight Rating on Standard BioTools Inc (LAB)
-
SetPoint Medical Raises $140 Million in Private Financing and Expands Leadership Team to Support Commercialization of Rheumatoid Arthritis Therapy
-
Form SCHEDULE 13G Fortive Corp Filed by: VIKING GLOBAL INVESTORS LP
-
BiomEdit Advances First-of-Its-Kind Engineered Bacteria Product to Final Development Phase, Secures Series B Funding, Adds Key Industry Leadership
-
Form SCHEDULE 13D/A BridgeBio Pharma, Inc. Filed by: VIKING GLOBAL INVESTORS LP
-
Form SCHEDULE 13G Primo Brands Corp Filed by: VIKING GLOBAL INVESTORS LP
-
Antheia Raises $56 Million in Series C Financing to Fuel Global Commercialization Strategy
-
Mythic Therapeutics Presents Compelling Efficacy Data from its Phase 1 KisMET-01 Study Supporting Best-in-Class Potential of Novel cMET- ADC, MYTX-011, in Non-Small Cell Lung Cancer at the American So
-
ORIC Pharmaceuticals Inc. (ORIC) Announces $125 Million Private Placement at $6.50/sh
-
ORIC® Pharmaceuticals Announces $125 Million Private Placement Financing
-
Mythic Therapeutics to Present Compelling Efficacy Data from Phase 1 KisMET-01 Study Supporting Best-in-Class Potential of Investigational cMET ADC, MYTX-011, in Non-Small Cell Lung Cancer
-
Form SCHEDULE 13G/A Trevi Therapeutics, Inc. Filed by: VIKING GLOBAL INVESTORS LP
-
Form SCHEDULE 13G/A Oric Pharmaceuticals, Filed by: VIKING GLOBAL INVESTORS LP
-
Form SCHEDULE 13G/A Roivant Sciences Ltd. Filed by: VIKING GLOBAL INVESTORS LP
-
Form SCHEDULE 13G ACUREN CORP Filed by: VIKING GLOBAL INVESTORS LP
-
Form 13F-HR VIKING GLOBAL INVESTORS For: Mar 31
-
Mythic Therapeutics to Present Updated Dose Escalation Data from Phase 1 KisMET-01 Study on MYTX-011 at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Canopy Secures $70 Million Series C to Unclunk Accounting Firms with AI
-
DEBRA Research Announces Impact Investment into Nova Anchora to Advance Protein Therapy for Epidermolysis Bullosa
-
Mythic Therapeutics Presents Preclinical Data Demonstrating Potent Efficacy of MYTX-011 Across a Broad Range of Tumor Xenograft Models Harboring Clinically Relevant Mutations at the American Associati
-
Form SCHEDULE 13G REGAL REXNORD CORP Filed by: VIKING GLOBAL INVESTORS LP
-
Neurona Therapeutics Raises $102 Million to Fuel NRTX-1001 Phase 3 EPIC Epilepsy Trial and Advance Regenerative Cell Therapy Pipeline
-
Revive Environmental and Battelle Partner on DoD-Funded Project to Eliminate Toxic “Forever Chemicals”
-
Pearl Health Achieves HITRUST r2 Certification Demonstrating the Highest Level of Information Protection Assurance
-
Areteia Therapeutics Announces Appointments of Donald J. Hayden, Jr. and Ian F. Smith to Its Board of Directors
-
North Carolina Selects Revive Environmental for Statewide PFAS Destruction in AFFF Take-Back Program
-
Revive Environmental Welcomes Douglas Hendry as Chief Technology Officer
-
Patina Launches New Service, Patina Total Health (TM), to Make Personalized, Age-Friendly Care Accessible to Medicare Advantage Members
-
Form SCHEDULE 13D/A BridgeBio Pharma, Inc. Filed by: VIKING GLOBAL INVESTORS LP
-
Form SCHEDULE 13D/A Cazoo Group Ltd Filed by: VIKING GLOBAL INVESTORS LP
-
Form SCHEDULE 13G Sionna Therapeutics, Filed by: VIKING GLOBAL INVESTORS LP
-
Form SCHEDULE 13G/A NewAmsterdam Pharma Co Filed by: VIKING GLOBAL INVESTORS LP
-
Form SCHEDULE 13G/A Longboard Pharmaceutical Filed by: VIKING GLOBAL INVESTORS LP
-
Form SCHEDULE 13G/A APi Group Corp Filed by: VIKING GLOBAL INVESTORS LP
-
Hedge fund Viking buys Boeing shares, adds more JPMorgan, filing shows
